JUBILANT LIFE SCIENCES
BSE Code: 530019
Jubilant Life Sciences has been able to consistently improve its business over the last five to six quarters. For Q1FY13, its topline grew by 31 per cent on a YoY basis, which was driven by a strong pharma business and a fairly steady performance of its ingredients business. Its EBITDA margin improved by a huge 222 basis points on a YoY basis during the June 2012 quarter. The management expects a strong revenue growth of more than 20 per cent in FY13, along with stable margins.
The company has brought down its capex plan for FY13 to Rs 350 crore as against an average Rs 500 crore that it spent over the past five years. The company has a robust pipeline of products, with 20 approved ANDAs in the US of the total 48 filed. The API filings are also impressive, with 58 USDMFs. We believe that the company is likely to keep up with its performance going forward too and beat the street’s estimates. One can look at the scrip from a medium-term perspective.*To get the password for buy calls, please subscribe to this blog. You will receive the password in next email to you*